CYTOKINETICS INC (CYTK) — insider trading
Health Care · NASDAQ
CYTOKINETICS INC (CYTK) has 173 reported SEC Form 4 insider transactions in our data, including 26 open-market sales among the most recent 100 (latest 2026-10-20).
Recent Form 4 transactions
Showing the 100 most recent of 173 recorded transactions. See all on SEC EDGAR →
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-20 | Malik Fady Ibraham | Officer (EVP Research & Development) | Option exercise / conversion (derivative) | 3,500 | — | $0 | Form 4 |
| 2026-10-20 | Malik Fady Ibraham | Officer (EVP Research & Development) | Open-market sale | 3,500 | $64.01 | $224.0K | Form 4 |
| 2026-10-20 | Malik Fady Ibraham | Officer (EVP Research & Development) | Option exercise / conversion | 3,500 | $7.80 | $27.3K | Form 4 |
| 2026-10-16 | Wysenski Nancy | Director | Grant / award / vesting | 97 | $63.92 | $6.2K | Form 4 |
| 2026-10-16 | Kaye Edward M. MD | Director | Grant / award / vesting | 195 | $63.92 | $12.5K | Form 4 |
| 2026-10-16 | Harrington Robert Arthur | Director | Grant / award / vesting | 195 | $63.92 | $12.5K | Form 4 |
| 2026-10-16 | Daly James M | Director | Grant / award / vesting | 195 | $63.92 | $12.5K | Form 4 |
| 2026-10-16 | WIERENGA WENDELL | Director | Grant / award / vesting | 97 | $63.92 | $6.2K | Form 4 |
| 2026-10-16 | HENDERSON JOHN T | Director | Grant / award / vesting | 352 | $63.92 | $22.5K | Form 4 |
| 2026-10-12 | Blum Robert I | Director, Officer (President & CEO) | Option exercise / conversion (derivative) | 7,500 | — | $0 | Form 4 |
| 2026-10-12 | Blum Robert I | Director, Officer (President & CEO) | Open-market sale | 7,500 | $62.88 | $471.6K | Form 4 |
| 2026-10-12 | Blum Robert I | Director, Officer (President & CEO) | Option exercise / conversion | 7,500 | $10.60 | $79.5K | Form 4 |
| 2026-10-06 | Malik Fady Ibraham | Officer (EVP Research & Development) | Option exercise / conversion (derivative) | 3,500 | — | $0 | Form 4 |
| 2026-10-06 | Malik Fady Ibraham | Officer (EVP Research & Development) | Open-market sale | 3,500 | $61.38 | $214.8K | Form 4 |
| 2026-10-06 | Malik Fady Ibraham | Officer (EVP Research & Development) | Option exercise / conversion | 3,500 | $7.80 | $27.3K | Form 4 |
| 2026-09-28 | Blum Robert I | Director, Officer (President & CEO) | Option exercise / conversion (derivative) | 7,500 | — | $0 | Form 4 |
| 2026-09-28 | Blum Robert I | Director, Officer (President & CEO) | Open-market sale | 7,500 | $65.46 | $490.9K | Form 4 |
| 2026-09-28 | Blum Robert I | Director, Officer (President & CEO) | Option exercise / conversion | 7,500 | $10.60 | $79.5K | Form 4 |
| 2026-09-22 | Malik Fady Ibraham | Officer (EVP Research & Development) | Option exercise / conversion (derivative) | 3,500 | — | $0 | Form 4 |
| 2026-09-22 | Malik Fady Ibraham | Officer (EVP Research & Development) | Open-market sale | 3,500 | $68.29 | $239.0K | Form 4 |
| 2026-09-22 | Malik Fady Ibraham | Officer (EVP Research & Development) | Option exercise / conversion | 3,500 | $7.80 | $27.3K | Form 4 |
| 2026-09-15 | Landry Robert E | Director | Open-market sale | 1,000 | $72.13 | $72.1K | Form 4 |
| 2026-09-15 | Blum Robert I | Director, Officer (President & CEO) | Open-market sale | 97,926 | $69.33 | $6.79M | Form 4 |
| 2026-09-14 | Blum Robert I | Director, Officer (President & CEO) | Option exercise / conversion (derivative) | 7,500 | — | $0 | Form 4 |
| 2026-09-14 | Blum Robert I | Director, Officer (President & CEO) | Bona fide gift | 97,926 | — | $0 | Form 4 |
| 2026-09-14 | Blum Robert I | Director, Officer (President & CEO) | Bona fide gift | 97,926 | — | $0 | Form 4 |
| 2026-09-14 | Blum Robert I | Director, Officer (President & CEO) | Bona fide gift | 1,350 | — | $0 | Form 4 |
| 2026-09-14 | Blum Robert I | Director, Officer (President & CEO) | Open-market sale | 7,500 | $73.44 | $550.8K | Form 4 |
| 2026-09-14 | Blum Robert I | Director, Officer (President & CEO) | Option exercise / conversion | 7,500 | $10.60 | $79.5K | Form 4 |
| 2026-09-11 | Landry Robert E | Director | Open-market sale | 1,000 | $74.66 | $74.7K | Form 4 |
| 2026-09-08 | Malik Fady Ibraham | Officer (EVP Research & Development) | Option exercise / conversion (derivative) | 3,500 | — | $0 | Form 4 |
| 2026-09-08 | Malik Fady Ibraham | Officer (EVP Research & Development) | Open-market sale | 3,500 | $75.46 | $264.1K | Form 4 |
| 2026-09-08 | Malik Fady Ibraham | Officer (EVP Research & Development) | Option exercise / conversion | 3,500 | $7.80 | $27.3K | Form 4 |
| 2026-09-01 | PARSHALL B LYNNE | Director | Open-market sale | 5,000 | $71.48 | $357.4K | Form 4 |
| 2026-08-31 | Callos Andrew | Officer (EVP, Chief Commercial Officer) | Option exercise / conversion (derivative) | 10,000 | — | $0 | Form 4 |
| 2026-08-31 | Callos Andrew | Officer (EVP, Chief Commercial Officer) | Open-market sale | 10,000 | $70.24 | $702.4K | Form 4 |
| 2026-08-31 | Callos Andrew | Officer (EVP, Chief Commercial Officer) | Option exercise / conversion | 10,000 | $23.26 | $232.6K | Form 4 |
| 2026-08-31 | Blum Robert I | Director, Officer (President & CEO) | Option exercise / conversion (derivative) | 7,500 | — | $0 | Form 4 |
| 2026-08-31 | Blum Robert I | Director, Officer (President & CEO) | Open-market sale | 7,500 | $70.24 | $526.8K | Form 4 |
| 2026-08-31 | Blum Robert I | Director, Officer (President & CEO) | Option exercise / conversion | 7,500 | $10.60 | $79.5K | Form 4 |
| 2026-08-18 | Malik Fady Ibraham | Officer (EVP Research & Development) | Option exercise / conversion (derivative) | 3,500 | — | $0 | Form 4 |
| 2026-08-18 | Malik Fady Ibraham | Officer (EVP Research & Development) | Open-market sale | 3,500 | $75.82 | $265.4K | Form 4 |
| 2026-08-18 | Malik Fady Ibraham | Officer (EVP Research & Development) | Option exercise / conversion | 3,500 | $7.80 | $27.3K | Form 4 |
| 2026-08-10 | Blum Robert I | Director, Officer (President & CEO) | Option exercise / conversion (derivative) | 7,500 | — | $0 | Form 4 |
| 2026-08-10 | Blum Robert I | Director, Officer (President & CEO) | Open-market sale | 7,500 | $76.76 | $575.7K | Form 4 |
| 2026-08-10 | Blum Robert I | Director, Officer (President & CEO) | Option exercise / conversion | 7,500 | $10.60 | $79.5K | Form 4 |
| 2026-07-30 | Callos Andrew | Officer (EVP, Chief Commercial Officer) | Option exercise / conversion (derivative) | 14,000 | — | $0 | Form 4 |
| 2026-07-30 | Callos Andrew | Officer (EVP, Chief Commercial Officer) | Open-market sale | 14,000 | $79.88 | $1.12M | Form 4 |
| 2026-07-30 | Callos Andrew | Officer (EVP, Chief Commercial Officer) | Option exercise / conversion | 14,000 | $23.26 | $325.6K | Form 4 |
| 2026-07-27 | Blum Robert I | Director, Officer (President & CEO) | Option exercise / conversion (derivative) | 7,500 | — | $0 | Form 4 |
| 2026-07-27 | Blum Robert I | Director, Officer (President & CEO) | Open-market sale | 7,500 | $80.87 | $606.5K | Form 4 |
| 2026-07-27 | Blum Robert I | Director, Officer (President & CEO) | Option exercise / conversion | 7,500 | $10.60 | $79.5K | Form 4 |
| 2026-07-21 | Malik Fady Ibraham | Officer (EVP Research & Development) | Option exercise / conversion (derivative) | 3,500 | — | $0 | Form 4 |
| 2026-07-21 | Malik Fady Ibraham | Officer (EVP Research & Development) | Open-market sale | 3,500 | $80.59 | $282.1K | Form 4 |
| 2026-07-21 | Malik Fady Ibraham | Officer (EVP Research & Development) | Option exercise / conversion | 3,500 | $7.80 | $27.3K | Form 4 |
| 2026-07-15 | Daly James M | Director | Grant / award / vesting | 151 | $82.62 | $12.5K | Form 4 |
| 2026-07-15 | Harrington Robert Arthur | Director | Grant / award / vesting | 151 | $82.62 | $12.5K | Form 4 |
| 2026-07-15 | HENDERSON JOHN T | Director | Grant / award / vesting | 272 | $82.62 | $22.5K | Form 4 |
| 2026-07-15 | Kaye Edward M. MD | Director | Grant / award / vesting | 151 | $82.62 | $12.5K | Form 4 |
| 2026-07-15 | WIERENGA WENDELL | Director | Grant / award / vesting | 75 | $82.62 | $6.2K | Form 4 |
| 2026-07-15 | Wysenski Nancy | Director | Grant / award / vesting | 75 | $82.62 | $6.2K | Form 4 |
| 2026-07-13 | Blum Robert I | Director, Officer (President & CEO) | Option exercise / conversion (derivative) | 7,490 | — | $0 | Form 4 |
| 2026-07-13 | Blum Robert I | Director, Officer (President & CEO) | Open-market sale | 7,490 | $82.02 | $614.3K | Form 4 |
| 2026-07-13 | Blum Robert I | Director, Officer (President & CEO) | Option exercise / conversion | 7,490 | $10.60 | $79.4K | Form 4 |
| 2026-07-13 | Blum Robert I | Director, Officer (President & CEO) | Open-market sale | 10 | $82.02 | $820 | Form 4 |
| 2026-07-07 | Malik Fady Ibraham | Officer (EVP Research & Development) | Option exercise / conversion (derivative) | 3,500 | — | $0 | Form 4 |
| 2026-07-07 | Malik Fady Ibraham | Officer (EVP Research & Development) | Open-market sale | 3,500 | $86.62 | $303.2K | Form 4 |
| 2026-07-07 | Malik Fady Ibraham | Officer (EVP Research & Development) | Option exercise / conversion | 3,500 | $7.80 | $27.3K | Form 4 |
| 2026-07-01 | Lee Sung | Officer (EVP, Chief Financial Officer) | Option exercise / conversion (derivative) | 1,112 | — | $0 | Form 4 |
| 2026-07-01 | Lee Sung | Officer (EVP, Chief Financial Officer) | Open-market sale | 1,112 | $87.79 | $97.6K | Form 4 |
| 2026-07-01 | Lee Sung | Officer (EVP, Chief Financial Officer) | Option exercise / conversion | 1,112 | $48.51 | $53.9K | Form 4 |
| 2026-07-01 | Callos Andrew | Officer (EVP, Chief Commercial Officer) | Option exercise / conversion (derivative) | 15,000 | — | $0 | Form 4 |
| 2026-07-01 | Callos Andrew | Officer (EVP, Chief Commercial Officer) | Open-market sale | 15,000 | $85.80 | $1.29M | Form 4 |
| 2026-07-01 | Callos Andrew | Officer (EVP, Chief Commercial Officer) | Option exercise / conversion | 15,000 | $23.26 | $348.9K | Form 4 |
| 2026-07-01 | Blum Robert I | Director, Officer (President & CEO) | Open-market sale | 7,500 | $84.92 | $636.9K | Form 4 |
| 2026-06-29 | Lee Sung | Officer (EVP, Chief Financial Officer) | Option exercise / conversion (derivative) | 823 | — | $0 | Form 4 |
| 2026-06-29 | Lee Sung | Officer (EVP, Chief Financial Officer) | Option exercise / conversion (derivative) | 188 | — | $0 | Form 4 |
| 2026-06-29 | Lee Sung | Officer (EVP, Chief Financial Officer) | Option exercise / conversion (derivative) | 1,113 | — | $0 | Form 4 |
| 2026-06-29 | Lee Sung | Officer (EVP, Chief Financial Officer) | Option exercise / conversion (derivative) | 822 | — | $0 | Form 4 |
| 2026-06-29 | Lee Sung | Officer (EVP, Chief Financial Officer) | Option exercise / conversion (derivative) | 188 | — | $0 | Form 4 |
| 2026-06-29 | Lee Sung | Officer (EVP, Chief Financial Officer) | Open-market sale | 3,134 | $85.00 | $266.4K | Form 4 |
| 2026-06-29 | Lee Sung | Officer (EVP, Chief Financial Officer) | Option exercise / conversion | 823 | $44.36 | $36.5K | Form 4 |
| 2026-06-29 | Lee Sung | Officer (EVP, Chief Financial Officer) | Option exercise / conversion | 188 | $44.36 | $8.3K | Form 4 |
| 2026-06-29 | Lee Sung | Officer (EVP, Chief Financial Officer) | Option exercise / conversion | 1,113 | $48.51 | $54.0K | Form 4 |
| 2026-06-29 | Lee Sung | Officer (EVP, Chief Financial Officer) | Option exercise / conversion | 822 | $44.36 | $36.5K | Form 4 |
| 2026-06-29 | Lee Sung | Officer (EVP, Chief Financial Officer) | Option exercise / conversion | 188 | $44.36 | $8.3K | Form 4 |
| 2026-06-24 | Lee Sung | Officer (EVP, Chief Financial Officer) | Option exercise / conversion (derivative) | 1,113 | — | $0 | Form 4 |
| 2026-06-24 | Lee Sung | Officer (EVP, Chief Financial Officer) | Option exercise / conversion (derivative) | 822 | — | $0 | Form 4 |
| 2026-06-24 | Lee Sung | Officer (EVP, Chief Financial Officer) | Option exercise / conversion (derivative) | 188 | — | $0 | Form 4 |
| 2026-06-24 | Lee Sung | Officer (EVP, Chief Financial Officer) | Option exercise / conversion (derivative) | 1,113 | — | $0 | Form 4 |
| 2026-06-24 | Lee Sung | Officer (EVP, Chief Financial Officer) | Option exercise / conversion (derivative) | 2,817 | — | $0 | Form 4 |
| 2026-06-24 | Lee Sung | Officer (EVP, Chief Financial Officer) | Option exercise / conversion (derivative) | 9,307 | — | $0 | Form 4 |
| 2026-06-24 | Lee Sung | Officer (EVP, Chief Financial Officer) | Option exercise / conversion (derivative) | 23,370 | — | $0 | Form 4 |
| 2026-06-24 | Lee Sung | Officer (EVP, Chief Financial Officer) | Open-market sale | 38,730 | $82.30 | $3.19M | Form 4 |
| 2026-06-24 | Lee Sung | Officer (EVP, Chief Financial Officer) | Option exercise / conversion | 1,113 | $48.51 | $54.0K | Form 4 |
| 2026-06-24 | Lee Sung | Officer (EVP, Chief Financial Officer) | Option exercise / conversion | 822 | $44.36 | $36.5K | Form 4 |
| 2026-06-24 | Lee Sung | Officer (EVP, Chief Financial Officer) | Option exercise / conversion | 188 | $44.36 | $8.3K | Form 4 |
| 2026-06-24 | Lee Sung | Officer (EVP, Chief Financial Officer) | Option exercise / conversion | 1,113 | $48.51 | $54.0K | Form 4 |
| 2026-06-24 | Lee Sung | Officer (EVP, Chief Financial Officer) | Option exercise / conversion | 2,817 | $44.36 | $125.0K | Form 4 |
| 2026-06-24 | Lee Sung | Officer (EVP, Chief Financial Officer) | Option exercise / conversion | 9,307 | $44.36 | $412.9K | Form 4 |
Ask the chat about CYTK's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: CYTOKINETICS INC (CYTK).
Last updated 2026-10-20 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.